Abstract
Lung cancer is the leading cause of cancer-related death. The majority of patients are diagnosed at an incurable advanced stage with poor prognosis. A recent study associated the methylation of homologous recombination genes with expression of immune checkpoints in lung squamous cell carcinoma. However, the correlation between them remains unclear. In our study, we propose that RAD51B, a repair gene in the homologous recombination process, which is noticed to be a key player in the maintenance of chromosome integrity and in sensing DNA damage, can act as an independent factor affecting the prognosis of non-small-cell lung cancer (NSCLC). Univariate analysis showed that overexpression of RAD51B is statistically significant correlated with better prognosis (P=0.013). Further, the multivariate Cox regression analysis showed that the morbidity of patients with high expression of RAD51B was decreased by 26% compared to those with low expression (HR=0.74, 95%CI: 0.59-0.93), especially for the patients with squamous cell carcinoma (HR=0.68, 95%CI: 0.51-0.90). In conclusion, RAD51B in mRNA level can be an important indicator to decide the prognosis of NSCLC and its overexpression predicts a preferable prognosis for NSCLC. Our results serve as a foundation for the investigation of the role of RAD51B in NSCLC, which may lead to potential therapeutic innovations.
Highlights
Lung cancer remains the most frequently diagnosed cancer worldwide and the leading cause of cancer-related deaths
We propose that RAD51B, a repair gene in the homologous recombination process, which is noticed to be a key player in the maintenance of chromosome integrity and in sensing DNA damage, can act as an independent factor affecting the prognosis of non-small-cell lung cancer (NSCLC)
We analyzed the relationship between the prognosis of NSCLC and RAD51 family mRNA levels that are available from the The Cancer Genome Atlas database (TCGA) database, including RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3, no significant correlation was found except for RAD51B
Summary
Lung cancer remains the most frequently diagnosed cancer worldwide and the leading cause of cancer-related deaths. Over half of patients die within one year after being diagnosed with lung cancer and the 5-year survival rate is only about 17.8% [1]. Therein, non-small-cell lung carcinoma (NSCLC) accounts for approximately 85% of all these cases. Due to its characteristics of high recurrence and metastasis after surgery, the clinical prognosis is unfavorable, particular if diagnosed at a later stage. Finding significant, early-presented, prognosis factors of NSCLC can aid prompt treatment. The clinical prognosis factors currently available only exhibit in a small fraction of NSCLC deaths. There is a need to explore new biomarkers that correlate with morbidity of NSCLC patients. Targetable mutations and targeted therapy resistance development in 50% of NSCLC cases emphasizes the significance for developing new prognostic indicators and alternative therapeutic strategies for treating NSCLC [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
